#1 Clinical Trials Search in Europe

Galcanezumab

Galcanezumab, also known by the brand name Emgality, is a calcitonin gene-related peptide (CGRP) antagonist that has shown promise in clinical trials for the prevention and treatment of migraine. This article summarizes key findings from various clinical trials investigating the efficacy, safety, and tolerability of galcanezumab in patients with episodic and chronic migraine, as well as its potential applications for other conditions like cluster headache and neuropathic pain.

Table of Contents

What is Galcanezumab?

Galcanezumab, also known by the brand name Emgality, is a medication used for the prevention of migraine headaches in adults[1]. It belongs to a class of drugs called calcitonin gene-related peptide (CGRP) antagonists, which work by blocking a protein involved in migraine pain[2].

How Does It Work?

Galcanezumab works by targeting and blocking a protein called CGRP. This protein is believed to play a key role in causing migraine pain. By blocking CGRP, galcanezumab can help prevent migraine attacks from occurring[2]. This mechanism of action makes it different from many other migraine prevention medications that work on other pathways in the brain.

What Conditions Does Galcanezumab Treat?

Galcanezumab is primarily used to treat and prevent:

  • Episodic migraine: This refers to having migraine headaches on fewer than 15 days per month[3].
  • Chronic migraine: This is defined as having headaches on 15 or more days per month, with at least 8 of those days involving migraine symptoms[3].
  • Cluster headache: Some studies have also investigated the use of galcanezumab for both episodic and chronic cluster headaches, which are severe headaches that occur in cyclical patterns[4].

How is Galcanezumab Administered?

Galcanezumab is given as a subcutaneous (under the skin) injection. Typically, the treatment regimen involves:

  • An initial loading dose of 240 mg (two 120 mg injections)
  • Followed by monthly doses of 120 mg
The medication can be self-administered at home using either an auto-injector or a pre-filled syringe[1].

Effectiveness of Galcanezumab

Clinical trials have shown that galcanezumab can be effective in reducing the number of migraine days per month. Some key findings include:

  • Reduction in monthly migraine days: Many patients experience a significant decrease in the number of days they have migraines each month[5].
  • Improved quality of life: Patients often report improvements in their ability to function in daily life and work[5].
  • Decreased use of acute migraine medications: Many patients find they need to use fewer medications to treat acute migraine attacks[5].

Potential Side Effects

Like all medications, galcanezumab can cause side effects. The most commonly reported side effects include:

  • Injection site reactions (such as pain, redness, or swelling at the injection site)
  • Constipation
  • Itching
  • Rash
Serious side effects are rare, but can include allergic reactions. It’s important to discuss any side effects with your healthcare provider[1].

Use in Special Populations

Research is ongoing to understand the safety and effectiveness of galcanezumab in various populations:

  • Adolescents: Studies are being conducted to evaluate the use of galcanezumab in patients aged 12 to 17 years with chronic migraine[6].
  • Pregnant and breastfeeding women: Research is being done to understand how galcanezumab may affect breast milk and infant outcomes[7].
  • Treatment-resistant migraine: Some studies focus on patients who haven’t responded well to other migraine prevention treatments[5].

Ongoing Research

Scientists continue to study galcanezumab to better understand its long-term effects, optimal dosing, and potential use in other conditions. Some areas of ongoing research include:

  • Use in combination with other migraine treatments[2]
  • Effectiveness in different types of headache disorders, such as cluster headaches[4]
  • Potential use in other pain conditions, such as trigeminal neuralgia[8]

Aspect Details
Drug Name Galcanezumab (Brand name: Emgality)
Drug Class Calcitonin Gene-Related Peptide (CGRP) Antagonist
Primary Use Prevention of migraine in adults
Administration Subcutaneous injection, typically 240mg loading dose followed by 120mg monthly
Efficacy Reduction in monthly migraine days, improved quality of life, decreased use of acute medications
Safety Profile Generally well-tolerated; common side effects include injection site reactions, constipation, dizziness
Special Populations Limited data in pregnancy and breastfeeding; studies ongoing
Other Potential Uses Episodic cluster headache, treatment-resistant migraine, neuropathic pain (under investigation)

FAQ

  • What is galcanezumab and how does it work? Galcanezumab is a calcitonin gene-related peptide (CGRP) antagonist used for migraine prevention. It works by binding to and blocking the action of CGRP, a protein involved in pain signaling during migraine attacks.
  • How is galcanezumab administered? Galcanezumab is typically administered as a subcutaneous (under the skin) injection. The usual dosing regimen involves a loading dose of 240 mg, followed by monthly doses of 120 mg.
  • What are the main benefits of galcanezumab observed in clinical trials? Clinical trials have shown that galcanezumab can reduce the number of monthly migraine days, improve quality of life, and decrease the use of acute migraine medications. Some patients experience a 50% or greater reduction in migraine frequency.
  • Are there any side effects associated with galcanezumab? Common side effects may include injection site reactions, constipation, and dizziness. Most adverse events reported in clinical trials were mild to moderate in severity. Long-term safety studies are ongoing to further evaluate the drug's safety profile.
  • Can galcanezumab be used during pregnancy or while breastfeeding? There is limited data on the use of galcanezumab during pregnancy and breastfeeding. Some studies are investigating its presence in breast milk and potential effects on infants. It's important to discuss the risks and benefits with a healthcare provider before using galcanezumab during pregnancy or lactation.

Ongoing Clinical Trials on Galcanezumab

  • Study on Reducing Chronic Migraine Days with CGRP Antibodies and Botulinum Toxin A in Adults Aged 18-70

    Recruiting

    3 1 1
    Investigated drugs:
    Norway

  • Study on Galcanezumab for Preventing Chronic Migraine in Adolescents Aged 12 to 17

    Not recruiting

    3 1
    Investigated drugs:
    Denmark France Italy The Netherlands Spain

  • Study on Galcanezumab for Preventing Episodic Migraine in Children and Teens Aged 6 to 17

    Not recruiting

    3 1
    Investigated diseases:
    Investigated drugs:
    Denmark Italy The Netherlands Spain

Glossary

  • Calcitonin Gene-Related Peptide (CGRP): A protein involved in pain signaling and inflammation, particularly in migraine. Galcanezumab works by blocking CGRP.
  • Episodic Migraine: A condition characterized by having fewer than 15 headache days per month, with at least some of these being migraine headaches.
  • Chronic Migraine: A condition characterized by 15 or more headache days per month, with at least 8 of these being migraine headaches, for more than 3 months.
  • Migraine Headache Day (MHD): A calendar day on which a migraine headache or probable migraine headache occurred, often used as a measure in clinical trials.
  • Subcutaneous Injection: A method of administering medication by injecting it into the layer of tissue beneath the skin.
  • Loading Dose: An initial higher dose of medication given at the beginning of treatment to quickly achieve effective levels in the body.
  • Treatment-Resistant Migraine: Migraine that has not responded adequately to multiple previous preventive treatments.
  • Anti-Drug Antibodies (ADA): Antibodies produced by the body against a therapeutic drug, which can potentially affect its efficacy or safety.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Quality of Life (QoL): A measure of an individual's overall well-being and ability to function in daily life, often assessed in clinical trials using specific questionnaires.

References

  1. https://clinicaltrials.gov/study/NCT02614287
  2. https://clinicaltrials.gov/study/NCT05492695
  3. https://clinicaltrials.gov/study/NCT02959190
  4. https://clinicaltrials.gov/study/NCT02797951
  5. https://clinicaltrials.gov/study/NCT03559257
  6. https://clinicaltrials.eu/trial/study-on-galcanezumab-for-preventing-chronic-migraine-in-adolescents-aged-12-to-17/
  7. https://clinicaltrials.gov/study/NCT06085144
  8. https://clinicaltrials.gov/study/NCT04158752